Bristol Myers Squibb Co (BMY): Share Repurchases
$0
Year ended 2025-12-31
| Period ended | Share Repurchases | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | n/a | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $0 | -100.0% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $5.16B | -35.6% | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $8.00B | +27.3% | 2025-02-12, From 2022-01-01 |
| 2021-12-31 | $6.29B | +306.7% | 2024-02-13, From 2021-01-01 |
| 2020-12-31 | $1.55B | -78.8% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $7.30B | n/m | 2022-02-09, From 2019-01-01 |
| 2018-12-31 | $320.00M | -87.0% | 2021-02-10, From 2018-01-01 |
| 2017-12-31 | $2.47B | +968.8% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $231.00M | n/a | 2019-02-25, From 2016-01-01 |
| No annual figure between 2013-12-31 and 2016-12-31. | |||
| 2013-12-31 | $433.00M | -82.0% | 2016-02-12, From 2013-01-01 |
| 2012-12-31 | $2.40B | +96.8% | 2015-02-13, From 2012-01-01 |
| 2011-12-31 | $1.22B | +112.0% | 2014-02-14, From 2011-01-01 |
| 2010-12-31 | $576.00M | n/a | 2013-02-15, From 2010-01-01 |
Share Repurchases at similar companies
| Company | Year ended | Share Repurchases | Change YoY |
|---|---|---|---|
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $0 | n/a |
| Abbott Laboratories (ABT) | 2025-12-31 | $893.00M | -31.0% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $980.00M | -42.6% |
| Pfizer Inc (PFE) | 2024-12-31 | $0 | n/a |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $5.08B | +289.3% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $4.11B | +64.3% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $5.95B | +144.8% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $3.44B | +32.1% |
| Viatris Inc (VTRS) | 2025-12-31 | $500.50M | +100.2% |
Compare BMY, ABT, ABBV, PFE side by side · Screen every company in Pharmaceutical Preparations ↗